Urelumab
Urelumab is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.
Urelumab targets the extracellular domain of CD137. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.
The first phase I trial began in 2006 and final results were published in 2015.
Current clinical trials combine urelumab with chemotherapy, chemoradiation, ipilimumab, rituximab, cetuximab, and elotuzumab
, nivolumab for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.
